Business Context and Reporting Period
Acurx Pharmaceuticals, Inc. (ACXP), an emerging growth company incorporated in Delaware, filed this Form 8-K on February 24, 2025. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's continued listing status.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate governance and listing compliance matter.
Material Changes
The material event reported is the receipt of a Nasdaq notification stating that the company's common stock failed to maintain a minimum closing bid price of $1.00 per share for the preceding 31 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). There is no immediate effect on the listing or trading of the stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has a 180-day grace period ending August 25, 2025, to regain compliance.
- Path to Compliance: Compliance is achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days during the grace period.
- Alternative Measures: If the price requirement is not met by the deadline, the company may seek an additional compliance period by meeting market value standards and potentially effecting a reverse stock split.
- Risks: There is no assurance the company will regain compliance or receive an extension. Failure to cure the deficiency could result in delisting, subject to an appeal process.
- Management Action: Management intends to actively monitor the bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of ACXP to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor future filings for announcements regarding a reverse stock split or other capital structure changes.
- Review the company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.
- Check for any subsequent Nasdaq communications regarding the status of the delisting notice.